U.S. Gas Utilities Stock News

NYSE:BAH
NYSE:BAHProfessional Services

Is Booz Allen Hamilton (BAH) Pricing Reflect Its 36% Share Price Slide And DCF Upside Potential

If you are wondering whether Booz Allen Hamilton Holding stock is offering value at current levels, a useful starting point is to look closely at what the recent share performance and fundamentals are actually showing. The stock last closed at US$76.28, with a 0.2% decline over 7 days, an 8.9% decline over 30 days, a 10.1% decline year to date and a 36.5% decline over the past year. This naturally raises questions about whether the risk and reward are now better balanced. Recent headlines...
NYSE:SMG
NYSE:SMGChemicals

Scotts Miracle-Gro Lawsuit Puts Governance And Valuation Gap In Focus

A federal judge has allowed key investor fraud claims against Scotts Miracle-Gro (NYSE:SMG) to proceed, focusing on alleged misstatements around demand, inventory, and the Hawthorne cannabis unit. The ruling keeps senior management and the company under legal scrutiny, extending an ongoing securities lawsuit rather than dismissing it outright. This development adds a layer of litigation and governance risk that sits alongside existing discussions of earnings, debt, and recovery efforts. For...
NYSE:FBIN
NYSE:FBINBuilding

Assessing Fortune Brands Innovations (FBIN) Valuation After Leadership Upheaval And Pre Q1 2026 Earnings

Recent leadership changes at Fortune Brands Innovations (FBIN), including interim management following activist investor pressure and a canceled CEO appointment, have put the stock in focus ahead of the Q1 2026 earnings report. See our latest analysis for Fortune Brands Innovations. The leadership turmoil and fresh dividend declaration are playing out against a share price that has fallen around 33% over 90 days and a 1 year total shareholder return of about 15% in decline. Shorter term price...
NasdaqGS:ACLS
NasdaqGS:ACLSSemiconductor

Axcelis Technologies (ACLS) Valuation As Q1 2026 Earnings And Margin Concerns Draw Closer Attention

Axcelis Technologies (ACLS) is approaching a closely watched catalyst, with Q1 2026 results and an earnings call scheduled for May 7. Analysts are focusing on profitability pressures and softer revenue expectations. See our latest analysis for Axcelis Technologies. The stock has been on a sharp upswing, with a 1 month share price return of 75.38% and year to date share price return of 98.56%, while the 1 year total shareholder return is 194.42%. This indicates strong momentum into the Q1 2026...
NYSE:LUMN
NYSE:LUMNTelecom

Lumen Technologies (LUMN) Q1 Losses Reinforce Bearish Narrative On Profitability

Lumen Technologies (LUMN) opened Q1 2026 with revenue of US$2.9 billion and a basic EPS loss of US$0.20, alongside net income excluding extra items of a US$200 million loss. Over recent quarters, revenue moved from US$3.3 billion in Q4 2024 to US$3.2 billion in Q1 2025 and US$3.0 billion in Q4 2025. Basic EPS shifted from a profit of US$0.09 in Q4 2024 to losses of US$0.20 in Q1 2025 and US$0.00 in Q4 2025. Taken together, these figures frame Q1 2026 as another period where investors are...
NasdaqGS:CROX
NasdaqGS:CROXLuxury

A Look At Crocs (CROX) Valuation As Mixed Q1 Results Meet A Raised Full Year Earnings Outlook

Why Crocs stock is back in focus after mixed earnings and guidance Crocs (CROX) just reported first quarter 2026 results showing lower sales and net income year over year, while at the same time tightening second quarter guidance and raising its full year earnings outlook. The combination of softer recent performance and a more confident full year earnings range is giving investors fresh information on how the company sees demand, profitability and its broader footwear portfolio for the rest...
NasdaqGS:FLYW
NasdaqGS:FLYWDiversified Financial

Flywire (FLYW) Q1 EPS Rebound Tests Bullish High‑Growth Narratives

Flywire (FLYW) has kicked off Q1 2026 with total revenue of US$188.1 million, basic EPS of US$0.10, and trailing twelve month EPS of US$0.24, alongside very large year over year earnings growth and a net profit margin reported at 4.5% versus 1% a year ago. Over recent quarters the company has seen revenue move from US$117.6 million in Q4 2024 to US$133.5 million in Q1 2025, US$131.9 million in Q2 2025, US$200.1 million in Q3 2025, US$157.5 million in Q4 2025, and now US$188.1 million in Q1...
NasdaqGS:SRPT
NasdaqGS:SRPTBiotechs

A Look At Sarepta Therapeutics (SRPT) Valuation After Its First Quarter Profit Turnaround

Sarepta Therapeutics (SRPT) stock is reacting to first quarter earnings, where revenue of US$730.8 million compared with US$744.86 million a year earlier, while net income reached US$330.96 million after a prior net loss. See our latest analysis for Sarepta Therapeutics. The latest earnings reversal has arrived after a volatile stretch, with a 90 day share price return of 35.23% and a 1 year total shareholder return decline of 37.28%, suggesting that recent momentum contrasts with longer term...
NYSE:UHS
NYSE:UHSHealthcare

Did Strong Q1 Results, Buybacks and Talkspace Financing Just Shift Universal Health Services' (UHS) Investment Narrative?

In the first quarter of 2026, Universal Health Services reported higher revenue of US$4,495.18 million and net income of US$348.68 million, while also repurchasing 675,000 shares for US$127.3 million and arranging up to US$900 million in new credit facilities partly to fund its Talkspace acquisition. This combination of stronger profitability, continued share repurchases, and additional financing capacity suggests management is actively reshaping the company’s capital structure and...
NYSE:OVV
NYSE:OVVOil and Gas

Is It Too Late To Consider Ovintiv (OVV) After Its 81.8% One Year Rally?

Investors may be wondering whether Ovintiv's share price still offers value after a strong run, or if most of the opportunity is already reflected in the stock. The stock last closed at US$59.90, with returns of 47.9% year to date and 81.8% over the past year. Over the past 7 days the return was a 1.9% decline, and over the past 30 days the return was 0.8%. Recent price moves have drawn attention to how the market is currently weighing Ovintiv's prospects against its risks. Ongoing sector...
NYSE:BKV
NYSE:BKVOil and Gas

Will BKV’s (BKV) Profit Rebound and Low‑Carbon Push Redefine Its Integrated Energy Narrative?

BKV Corporation has reported first-quarter 2026 results, with revenue of US$432.85 million versus US$176.07 million a year earlier and net income of US$44.08 million, compared with a net loss of US$81.98 million, alongside a successful equity raise of US$186.2 million. The company’s return to profitability, combined with progress in its power and carbon capture projects and increased ownership in its BKV-BPP Power joint venture, underpins a broader shift toward integrated low‑carbon energy...
NasdaqGS:KLAC
NasdaqGS:KLACSemiconductor

KLA Stock Split And Dividend Hike Meet Terafab AI Chip Opportunity

KLA (NasdaqGS:KLAC) announced a ten-for-one stock split alongside a 21% increase in its dividend. The company is also positioned to supply inspection and process control equipment to the planned Terafab U.S. chip fabrication project focused on advanced AI processors. These developments are new for KLA and are expected to influence how investors think about the stock and its role in future U.S. chip production. For context, KLA shares recently closed at $1,816.29, with the stock up 17.9%...
NasdaqGS:ADPT
NasdaqGS:ADPTLife Sciences

Adaptive Biotechnologies Q1 Loss Deepens Again And Tests Profitability Improvement Narrative

Adaptive Biotechnologies (ADPT) opened Q1 2026 with revenue of US$70.9 million and a basic EPS loss of US$0.13, alongside a net loss of US$20.0 million. Over recent quarters the company has seen revenue move from US$47.5 million in Q4 2024 to US$52.4 million in Q1 2025, US$58.9 million in Q2 2025, US$94.0 million in Q3 2025 and US$71.7 million in Q4 2025. Quarterly EPS ranged from a loss of US$0.23 in Q4 2024 to a profit of US$0.06 in Q3 2025 and back to a loss of US$0.09 in Q4 2025, putting...
NYSE:CNA
NYSE:CNAInsurance

Assessing CNA Financial (CNA) Valuation After Weaker First Quarter 2026 Earnings And Underwriting Results

CNA Financial (CNA) is back in focus after first quarter 2026 results showed softer earnings and an underwriting setback in its core Property & Casualty business, alongside an ongoing cash dividend commitment. See our latest analysis for CNA Financial. The weaker first quarter earnings and underwriting results have coincided with a 7 day share price return of 9.12% and a 90 day share price return of 13.31%. The 3 year total shareholder return of 37.57% suggests momentum has been stronger over...
NYSE:GENI
NYSE:GENIHospitality

Does Liga MX GeniusIQ Rollout And Wider Losses Change The Bull Case For Genius Sports (GENI)?

Genius Sports Limited has reported first-quarter 2026 results, with sales rising to US$187.95 million from US$143.99 million a year earlier, while net loss widened to US$55.47 million and loss per share increased to US$0.21. Alongside these results, Genius Sports has rolled out its GeniusIQ data and AI platform across every Liga MX stadium, positioning its technology at the center of Mexican soccer’s officiating, fan engagement, and sponsorship infrastructure. Next, we’ll explore how Genius...
NasdaqCM:RMR
NasdaqCM:RMRReal Estate

Do RMR Group’s (RMR) Mixed Quarterly And Year‑To‑Date Profits Reveal A Deeper Earnings Shift?

The RMR Group Inc. has reported past second-quarter 2026 results, with sales rising to US$5.1 million while revenue fell to US$145.63 million, and quarterly net income declining to US$1.01 million, or US$0.05 per diluted share, compared with the prior year period. Over the first six months of fiscal 2026, higher sales but lower revenue coincided with net income improving to US$13.2 million, highlighting a contrast between weaker quarterly profitability and stronger year‑to‑date earnings. We...
NYSE:CCK
NYSE:CCKPackaging

Is Crown’s Margin Squeeze And India Expansion Altering The Investment Case For Crown Holdings (CCK)?

Crown Holdings’ recent first-quarter 2026 results showed sales rising to US$3,259 million while net income and earnings per share eased, and the company affirmed a quarterly dividend of US$0.35 per share payable on May 28, 2026. At the same time, Crown announced plans for a new beverage can plant in Northern India capable of producing about 2.20 billion cans annually, supported by long-term customer commitments that underline demand for aluminum packaging. With higher volumes but pressured...
NasdaqGS:UAL
NasdaqGS:UALAirlines

A Look At United Airlines (UAL) Valuation After Q1 Beat And Spirit Exit Tailwinds

United Airlines Holdings (UAL) stock is back in focus after Q1 2026 results came in ahead of expectations, with management leaning on tighter capacity and pricing to help offset fuel volatility and support margins. See our latest analysis for United Airlines Holdings. The recent 6.8% 1 day and 12.0% 30 day share price returns suggest momentum is rebuilding after a weaker period. The 1 year total shareholder return of 26.0% and 3 year total shareholder return of about 12x indicate longer term...
NasdaqGS:MRNA
NasdaqGS:MRNABiotechs

Moderna Flu Breakthrough Puts mRNA-1010 And Valuation In Focus

Moderna published Phase 3 results for its mRNA-1010 flu vaccine in the New England Journal of Medicine. The mRNA flu vaccine showed higher efficacy compared with standard seasonal flu shots. Regulatory filings are in progress in the US, EU, and other regions to seek approval for mRNA-1010. For investors watching NasdaqGS:MRNA, this flu update comes with the stock at $48.79 and a mixed return profile. The share price is up 6.7% over the past week, flat over 30 days, and higher by 58.1% year...
NYSE:WRB
NYSE:WRBInsurance

A Look At W. R. Berkley (WRB) Valuation As Shares Show Recent Weakness

Stock performance and recent context W. R. Berkley (WRB) has seen mixed share performance recently, with the stock near US$66 and returns showing modest movement over the past week and month, but a more pronounced decline over the past 3 months and year. See our latest analysis for W. R. Berkley. Recent trading has been soft, with a 90 day share price return of about a 7% decline and a 1 year total shareholder return of about a 7% decline, even though the 3 and 5 year total shareholder...
NasdaqGS:HOOD
NasdaqGS:HOODCapital Markets

Is It Too Late To Consider Robinhood Markets (HOOD) After Last Year’s 58% Rally?

Wondering if Robinhood Markets at around US$79 per share is still compelling value or if the easy gains are behind it? This article breaks down what the current price really reflects. The stock has been volatile recently, with an 11% return over the last 7 days, 13.3% over the last 30 days, a 31.4% decline year to date, and a 58.1% return over the last year, which can shift how the market is thinking about both opportunity and risk. Recent coverage has focused on Robinhood's evolving role in...
NYSE:MANE
NYSE:MANEPharmaceuticals

Assessing Veradermics (MANE) Valuation After A Sharp 72% One Month Share Price Move

What recent moves in Veradermics (MANE) might be telling you Veradermics (MANE) has drawn attention after a sharp month return of about 72% and a very large past 3 months move, putting its clinical stage dermatology pipeline and valuation in sharper focus for investors. See our latest analysis for Veradermics. The recent 72% 30 day share price return and very large 90 day move sit alongside a 190.78% year to date share price return, which points to strong upward momentum despite a 4.38% one...
NasdaqGS:UTHR
NasdaqGS:UTHRBiotechs

Is It Too Late To Consider United Therapeutics (UTHR) After Its 94% One Year Surge?

Investors may be wondering whether United Therapeutics at around US$596.76 is still offering value after a strong run, or if the easy gains are already behind it. The stock has recent returns of 4.5% over 7 days, 6.6% over 30 days, 20.1% year to date, 94.4% over 1 year and 181.2% over 3 years. This puts valuation questions front and center for anyone considering it today. Recent coverage has focused on United Therapeutics as a high growth biotech with a strong pipeline and regulatory...
NYSE:PIPR
NYSE:PIPRCapital Markets

Does Piper Sandler (PIPR) Pairing Dividend Hike And Buybacks Reveal Its True Capital Allocation Priorities?

In the past week, Piper Sandler Companies reported first-quarter 2026 revenue of US$475.15 million and net income of US$65.24 million, raised its quarterly dividend to US$0.20 per share, completed a US$61.55 million buyback program, and added healthcare investment banker Patrick McCormack, M.D., as a managing director. Together, the stronger-than-expected revenue, 14% dividend increase, continued share repurchases, and senior healthcare hire highlight management’s focus on shareholder...